Dipyridamole/Magnesium To Improve Sickle Cell Hydration

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the benefits as well as side effects of giving drugs called dipyridamole and magnesium to patients with sickle cell anemia (SCA).

• Phase: Phase 2

Details

• Lead Sponsor: Children's Hospital Medical Center, Cincinnati
• Treatments: Dipyridamole

Criteria

Inclusion Criteria:

• Patients with homozygous sickle cell (Hb SS) confirmed by hemoglobin electrophoresis or HPLC

• Patients with adequate cardiac, renal, and liver function

• Patients with baseline fetal hemoglobin (Hb F) level of 10% or less

• Patients with at least 6% dense cells or higher at initial screening visit

• Patients with no history of coronary heart disease

• Patients with normal baseline ECG

• Patients with no history of hypotension or hypotensive episodes

Exclusion Criteria:

• Patients who are pregnant, trying to become pregnant, or breast feeding

• Patients who are on a chronic transfusion program

• Patients who are unable to take oral medications

• Patients who have significant cardiac, renal, or liver dysfunction

• Patients who are on hydroxyurea

• Patients who have a fetal hemoglobin (Hgb F) level of greater than 10%, or have less than 6% dense cell on initial screen

• Patients who are taking a supplement which contains magnesium

• Patients who are taking aspirin, ibuprofen on a daily basis, or anti-coagulant such as Coumadin on a daily basis

• Patients who have a known underlying coagulopathy (acquired or congenital) or have prolonged PT or PTT at the time of initial screen

• Patients who have had a hypersensitivity to either of the study medications

• Patients who are taking any other study medication(s). Patients will not be excluded if they are on penicillin prophylaxis or folic acid, or use ibuprofen intermittently

• Patients taking tetracycline or sodium polystyrene sulfonate

• Patients on concomitant medications and other therapy must have a wash out period prior to study entry and/or study drug dosing

• Patients with abnormal baseline ECG

• Patients with a history of hypotension or hypotensive episodes